Dudediligence.

Longeveron Inc

LGVNNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$773,000Sep ’24$603,000Dec ’24$381,000Mar ’25$316,000Jun ’25$137,000Sep ’25$365,000Dec ’25$398,000Mar ’26$287,000Jun ’26
Net income, by quarter
−$4.4MSep ’24−$4.1MDec ’24−$5.0MMar ’25−$5.0MJun ’25−$7.2MSep ’25−$5.4MDec ’25−$4.7MMar ’26−$6.1MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$708,000$940,000$709,000$2.4M$1.2M
Gross profit$590,000$497,000$221,000$1.9M$803,000
Operating income−$17.5M−$18.0M−$21.0M−$16.5M−$23.3M
Net income−$17.0M−$18.8M−$21.4M−$16.0M−$22.7M
Operating cash flow−$9.6M−$14.0M−$19.0M−$13.9M−$18.6M
Free cash flow−$10.0M−$14.5M−$19.3M−$14.5M−$18.9M
Cash$25.7M$10.5M$4.9M$19.2M$4.7M
Shares outstanding18.9M21.0M2.17B9.41B17.58B